ENB Therapeutics Email Format

Pharmaceutical ManufacturingNew York, United States2-10 Employees

ENB Therapeutics is a small biotechnology company focused on oncology therapies that address drug resistance seen in many cancer patients. Its lead candidate, ENB-001, is described as a selective endothelin B receptor inhibitor that preclinical data indicate can slow tumor growth, extend survival, and enhance immune cell infiltration into tumors while inhibiting metastasis. The company notes a relatively compact development path, with a near-term proof of concept expected within about 18 months after financing, supported by FDA Orphan Drug Designation and robust intellectual property. Headquartered in New York City, New York, ENB Therapeutics is positioned in the pharmaceutical manufacturing sector with a focus on oncology. Its collaboration history includes a 2019 clinical partnership with Merck to evaluate ENB-003 with pembrolizumab in advanced solid tumors, and a 2026 collaboration with HITLAB announced to advance its work in healthcare innovation.

Sign up for free to view info

Company overview Employee directory